- Home
- MOV vs FHTX Comparison
MOV vs FHTX Comparison
Compare MOV & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- FHTX
- Stock Information
- Founded
- MOV 1961
- FHTX 2015
- Country
- MOV United States
- FHTX United States
- Employees
- MOV N/A
- FHTX N/A
- Industry
- MOV Consumer Specialties
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- MOV Consumer Discretionary
- FHTX Health Care
- Exchange
- MOV Nasdaq
- FHTX Nasdaq
- Market Cap
- MOV 339.1M
- FHTX 278.1M
- IPO Year
- MOV 1993
- FHTX 2020
- Fundamental
- Price
- MOV $15.94
- FHTX $4.98
- Analyst Decision
- MOV Strong Buy
- FHTX Strong Buy
- Analyst Count
- MOV 1
- FHTX 8
- Target Price
- MOV $31.50
- FHTX $12.63
- AVG Volume (30 Days)
- MOV 110.9K
- FHTX 110.7K
- Earning Date
- MOV 09-04-2025
- FHTX 08-05-2025
- Dividend Yield
- MOV 8.78%
- FHTX N/A
- EPS Growth
- MOV N/A
- FHTX N/A
- EPS
- MOV 0.78
- FHTX N/A
- Revenue
- MOV $650,768,000.00
- FHTX $24,173,000.00
- Revenue This Year
- MOV $0.71
- FHTX $33.60
- Revenue Next Year
- MOV N/A
- FHTX $5.87
- P/E Ratio
- MOV $20.42
- FHTX N/A
- Revenue Growth
- MOV N/A
- FHTX N/A
- 52 Week Low
- MOV $12.85
- FHTX $2.95
- 52 Week High
- MOV $24.98
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- MOV 49.77
- FHTX 44.97
- Support Level
- MOV $15.67
- FHTX $4.48
- Resistance Level
- MOV $16.48
- FHTX $5.23
- Average True Range (ATR)
- MOV 0.42
- FHTX 0.39
- MACD
- MOV 0.03
- FHTX -0.07
- Stochastic Oscillator
- MOV 56.31
- FHTX 23.65
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.